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Type 2 innate lymphoid cells (ILC2s) are a potent source of 
the type 2 signature cytokines IL-13 and IL-5 that drive al-
lergic inflammation (Scanlon and McKenzie, 2012; Diefen-
bach et al., 2014; Klose and Artis, 2016). ILC2s are present in 
sputum and bronchoalveolar lavage (BAL) in human asthma 
(Christianson et al., 2015; Gordon et al., 2016; Smith et al., 
2016). They respond to the epithelial cell–derived cytokines 
IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) 
and may play a role in the initiation and/or maintenance 
of chronic airway inflammation. The mechanisms underly-
ing ILC2 development, homeostasis, and function have been 
the subject of intense investigation. The signaling modules 
and transcriptional programs that control ILC2 biology bear 
striking resemblance to those operative in tissue-homing 
TH2 cells that mediate similar functions in adaptive immu-
nity (Van Dyken et al., 2016). However, very little is known 
about the posttranscriptional regulation of ILC2 gene expres-
sion and immune function.
MicroRNAs (miRNAs) are ubiquitous posttranscrip-
tional repressors of gene expression that play critical roles in 
lymphocyte homeostasis and allergic responses (Deshpande 
et al., 2015; Pua and Ansel, 2015). Each miRNA regulates 
multiple mRNA targets, and individual mRNAs may be reg-
ulated by multiple miRNAs. In this way, miRNA-directed 
regulatory networks powerfully influence biological pro-
cesses despite the modest quantitative effect produced by 
each miRNA-target interaction. ILC2s express miR-155, and 
miR-155–deficient mice exhibit defective ILC2 and TH2 cell 
expansion and allergic airway (AA) inflammation (Okoye et 
al., 2014; Johansson et al., 2017). However, the expression and 
function of miRNAs in ILC2s remains largely unexplored.
The miR-17∼92 cluster of miRNAs is a particularly 
potent and pleiotropic regulator of B and T cell development, 
proliferation, survival, activation, differentiation, and cytokine 
production (Mogilyansky and Rigoutsos, 2013). The cluster 
is transcribed as a single primary miRNA transcript that is 
processed by the Drosha/Dgcr8 microprocessor complex 
and Dicer to produce six distinct mature miRNAs. These 
miRNAs can be classified by their target-determining seed 
sequences into four families: the miR-17 family (miR-17 
and miR-20a), the miR-18 family (miR-18a), the miR-19 
family (miR-19a and miR-19b-1), and the miR-92 fam-
ily (miR-92a-1). miR-19a is uniquely up-regulated in 
airway-infiltrating T cells from asthmatic subjects, and it pro-
motes TH2 cell cytokine production at least in part through 
direct targeting of the signaling inhibitors Pten, Socs1, and 
Tnfaip3 (which encodes A20; Simpson et al., 2014).
In the current study, we profiled and compared the 
miRNA transcriptomes of lung ILC2s and TH2 cells. miRNA 
expression was absolutely required to maintain ILC2 ho-
meostasis in vivo, and the miR-17∼92 cluster was partially 
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responsible for this function. In addition, miR-17∼92 pro-
moted IL-13 and IL-5 production in response to IL-33 and 
ILC2-driven type 2 inflammation in vivo. We established 
RNA transfection of ILC2s and showed that miR-19a 
or siRNAs against its targets, Socs1 or Tnfaip3, can res-
cue the defective cytokine production of miR-17∼92– 
deficient ILC2s. We conclude that miRNAs are crucial reg-
ulators of ILC2 biology that mediate similar but nonidenti-
cal programs of posttranscriptional gene regulation in innate 
and adaptive lymphocytes.
reSuLtS
ILc2 mirnAome shares features with tH2 cells
Small RNA sequencing was performed to define the 
ILC2 miRNAome. RNA was obtained from CD45+Lin–
Thy1.2+CD4–ST2+CD25+ ILC2s sorted from dissociated 
mouse lung tissue with or without three consecutive days of 
oropharyngeal IL-33 treatment. IL-33 instillation in the lungs 
expands and activates ILC2s (Bartemes et al., 2012; Kamijo 
et al., 2013), and we consistently recovered approximately 
twice as many ILC2s after IL-33 treatment. ILC2s were also 
analyzed after in vitro culture for 10 d in IL-33, TSLP, and 
IL-7. For comparison, RNA was collected from CD4+CD25–
CD62LhiCD44lo naive T cells from spleen and lymph nodes; 
CD4+4get+ TH2 cells from BAL after the induction of AA 
inflammation in 4get mice containing a bicistronic mRNA 
linking a readily identifiable reporter, enhanced GFP (EGFP), 
to IL-4 gene expression (Mohrs et al., 2001); and in vitro 
differentiated TH2 cells. Among all samples, 46–95% of se-
quence reads that mapped to the genome aligned to mature 
miRNAs. Contaminating rRNA, tRNA, and mRNA frag-
ments comprised, on average, just 9%, 4%, and 5% of mapped 
reads, respectively (Table S1).
Overall, there was a strong positive correlation between 
the global miRNA expression profiles of all ILC2 and T cell 
samples (Fig. 1 A). However, pairwise comparisons revealed 
differences between sample groups (Table S2). Unsupervised 
hierarchical clustering of 147 miRNAs with significant dif-
ferential expression (adjusted P < 0.01) in any pair of sample 
groups clustered the data by cell type (Fig. 1 B). Blocks of 
miRNAs with a shared signature were highlighted by this 
analysis, the largest being an “ILC2” block, a naive “CD4” 
block, and an “in vitro” block common to cultured ILC2 and 
T cells (Table S3). The expression profiles of ILC2s and ILC2s 
harvested after IL-33 administration in vivo were nearly iden-
tical. However, 14 miRNAs were significantly differentially 
expressed in ILC2s after 10 d of in vitro culture in IL-33 
(Fig. 1 C and Table S2).
The expression of this group of 14 miRNAs was also 
investigated in naive CD4+ T cells and in vitro–cultured TH2 
cells, revealing both shared and unique expression changes 
after in vitro activation of ILC2s and their adaptive lymphoid 
counterparts. miR-21a, miR-98, and miR-155 were similarly 
up-regulated, and miR-203, miR-151, and let-7c were simi-
larly down-regulated, in both ILC2s and TH2 cells (Fig. 1 C). 
miR-150 was also down-regulated in both cell types, though 
the effect size was larger in TH2 cells. Quantitative PCR 
analyses confirmed that miR-150 was down-regulated, and 
miR-155 and miR-21 up-regulated, in ILC2s cultured for 
10 d in IL-33 (Fig. 1 D). miR-146, a feedback inhibitor of 
NF-κB signaling that can be up-regulated in activated T cells 
under some conditions (Curtale et al., 2010; Rusca et al., 
2012; Yang et al., 2012), was also up-regulated in ILC2s cul-
tured in IL-33, but not in T cells cultured in TH2-polarizing 
conditions (Fig. 1 C; Monticelli et al., 2005).
A few miRNAs exhibited markedly different expression 
and regulation patterns in ILC2s and T cells. miR-126a ex-
pression was down-regulated from a mean of 8,000 reads per 
million (rpm) to 200 rpm after ILC2 culture in IL-33, but was 
up-regulated from 10 rpm in naive CD4+ T cells to 100 rpm 
during in vitro TH2 cell differentiation (Fig. 1 C and Table 
S4). In addition, three members of the large Mirc7 miRNA 
cluster on mouse chromosome 12, miR-541, miR-409, 
and miR-134, had very low baseline expression in ILC2s 
and naive CD4+ T cells but were up-regulated more than 
100-fold in cultured ILC2s. These miRNAs remained poorly 
expressed in cultured TH2 cells, but they were expressed in 
4get+ TH2 cells freshly isolated from AA samples at ∼30-fold 
higher abundance than in naive CD4+ T cells. The remaining 
members of the Mirc7 cluster were all expressed in relatively 
low amounts, typically <10 rpm. Full aligned miRNA se-
quence data are compiled in Table S4.
Severe reduction of lung ILc2s in mirnA-deficient mice
To investigate the overall requirements for miRNAs in 
ILC2 biology, we generated mice that lack the essential ca-
nonical miRNA biogenesis factor Dgcr8 in fluorescently 
marked ILC2s (hereafter termed Dgcr8Δ/Δ). Conditional 
Dgcr8-deficient mice (Rao et al., 2009) were intercrossed 
with Red5 mice (Nussbaum et al., 2013) in which Il5 is re-
placed with sequences encoding Cre recombinase and the 
fluorescent protein tdTomato, and with R26-YFP transgenic 
mice (Luche et al., 2007) to introduce a durable reporter of 
Cre expression. Total ILC2s in the lungs of Dgcr8+/− (Dgcr8- 
sufficient controls) and Dgcr8Δ/Δ (Dgcr8-deficient) mice were 
analyzed as live CD45+ CD90+lin−CD4−CD25+ (Fig. 2 A). 
Lung ILC2s identified in this way also expressed the IL-33 
receptor, ST2 (Fig. 2 B). Global loss of canonical miRNAs in 
these cells severely impaired ILC2 homeostasis. Flow cytomet-
ric analyses showed a marked reduction of total lung ILC2s 
in Dgcr8Δ/Δ mice compared with Dgcr8-sufficient controls 
(Fig.  2 C). A very severe defect was revealed by restricting 
analysis to YFP+ ILC2s, indicating that Dgcr8 deficiency is 
incompatible with long-term ILC2 survival (Fig. 2 D). Fur-
ther analysis of the impact of miRNA deficiency on ILC2 
function in these animals was precluded by the near absence 
of YFP+ Dgcr8Δ/Δ ILC2s (Fig. 2 E). Even ILC2s that expressed 
the Red5 tdTomato but had not yet established R26-YFP re-
porter expression were affected (Fig. 2 F). In contrast, there 
was no difference in the frequency of YFP–Red5– ILC2s that 
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Figure 1. Small rnA sequencing expression analysis of mirnAs in ILc2s and t cells. (A) Pearson correlation coefficients for global miRNA expression 
profiles among all samples. Sample groups include ILC2s isolated from naive mouse lung (ILC2), ILC2s isolated from mouse lung after IL-33 treatment (ILC2 
IL33), ILC2 cultured in vitro for 10 d (ILC2 in vitro), naive CD4 T cells (CD4), TH2 cells isolated from BAL of mice with AAs (TH2 AA), and TH2 cells polarized 
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lack evidence of current or prior Cre expression, indicating 
that ILC2s that retain miRNA expression did not expand 
to fill the niche left vacant by Dgcr8-deficient ILC2s. Col-
lectively, these results demonstrate that Dgcr8 deletion leads 
to ILC2 depletion, underscoring the importance of miRNA 
biogenesis for the maintenance of normal ILC2s in the lung.
the mir-17∼92 cluster regulates lung ILc2 homeostasis
Because of the severity of the defect caused by Dgcr8 defi-
ciency, further investigation of miRNA regulation of ILC2 
immune function requires examination of specific miRNAs 
expressed in ILC2s. The miR-17∼92 cluster of miRNAs 
exert powerful effects on lymphocyte homeostasis, differenti-
ation, and effector function, including TH2 cell cytokine pro-
duction (Mogilyansky and Rigoutsos, 2013; Simpson et al., 
2014). All six mature miRNA members of the miR-17∼92 
cluster (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, 
and miR-92a-1; Fig. 3 A) were expressed in freshly isolated 
and IL-33–stimulated ILC2s at abundances similar to those 
expressed in naive CD4+ T cells and TH2 cells (Fig.  3  B). 
To determine whether the miR-17∼92 cluster regu-
lates ILC2 homeostasis and function, we intercrossed mice 
in which the entire miR-17∼92 cluster is flanked by loxP 
sites with Red5 mice (hereafter termed 17∼92Δ/Δ). In ad-
dition, Cre-activatable R26–miR-17∼92 transgenic mice 
were intercrossed with Red5 mice to generate animals with 
fluorescently marked 17∼92tg/tg ILC2s overexpressing the 
miR-17∼92 cluster. miR-17∼92 cluster miRNA expression 
in Red5+ 17∼92Δ/Δ ILC2s was below the limit of detection 
or very low compared with miR-17∼92–sufficient control 
Red5+ 17∼92+/+ ILC2s (Fig. 3 C).
The miR-17∼92 cluster regulated the maintenance of 
lung ILC2s. The frequency of total and Red5+ ILC2s was 
reduced by almost 50% in 17∼92Δ/Δ mouse lungs com-
pared with miR-17∼92–sufficient Red5+ 17∼92+/+ con-
trol mice (Fig. 3 D). Conversely, 17∼92tg/tg mice bore more 
than twice the normal number of total and Red5+ ILC2s 
(Fig. 3 E). Thus, miR-17∼92 cluster miRNAs account for a 
significant proportion of the miRNA requirements for lung 
ILC2 homeostasis, although other miRNAs must also play 
major roles in this process.
the mir-17∼92 cluster promotes ILc2 
function in AA inflammation
Tissue-resident ILC2 cells expand and secrete IL-5 and IL-13 
in response to agents that incite type 2 inflammation. We used 
a mouse model of AA inflammation to test the generation 
and function of ILC2s in vivo and investigate the require-
ments for miR-17∼92 in an ILC2-mediated type 2 response. 
Mouse airways were challenged with the allergen papain on 
three consecutive days, and lung tissue samples were harvested 
on day 4 (Fig. 4 A). ILC2s expanded in response to papain in 
both 17∼92+/+ and 17∼92Δ/Δ mice, although the total num-
ber of ILC2s present in the lung was significantly lower in 
17∼92Δ/Δ mice (Fig. 4 B). To characterize and quantify airway 
inflammation, we analyzed BAL and digested lung tissue cells 
by flow cytometry. Airway and lung eosinophil infiltration 
was reduced in 17∼92Δ/Δ mice, whereas CD4+ T cell num-
bers were similar in both groups of mice (Fig. 4, C and D). 
Consistent with the observed type 2 inflammation, IL-13 was 
significantly induced by papain in the BAL fluid of 17∼92+/+, 
but not 17∼92Δ/Δ mice (Fig. 4 E). IL-5 protein was induced 
in the BAL of both groups of mice, but the Il5 mRNA was 
more abundant in 17∼92+/+ total lung cells (Fig. 4 F). Il13 
mRNA exhibited a similar trend but did not reach statistical 
significance. Papain-treated 17∼92Δ/Δ mice exhibited signifi-
cantly reduced frequencies of IL-5+, IL-13+, and IL-5/IL-13 
double-positive lung ILCs compared with 17∼92+/+ control 
mice (Fig. 4 G). Thus, miR-17∼92 deficiency in ILC2s de-
creased type 2 cytokine expression and eosinophilia, the hall-
marks of allergic lung inflammation.
To observe lung pathology, mice were challenged with 
papain on days 1, 3, and 5, and lung samples were harvested for 
histology 6 d after the initiation of papain treatment (Fig. 4 H). 
A persistent reduction in total inflammation was observed 
in 17∼92Δ/Δ mice (Fig. 4 I). Only sparse focal epithelial cell 
mucus metaplasia was observed by periodic acid–Schiff stain-
ing in tissue sections of either 17∼92+/+ or 17∼92Δ/Δ mice, 
precluding quantitative analysis (not depicted). However, 
IL-13–responsive genes that promote mucus production and 
tissue repair, including Muc5ac, Clca3, and Gob5 (Kuper-
man et al., 2002; Thai et al., 2005), were significantly lower in 
the epithelial brushings of papain-challenged 17∼92Δ/Δ mice 
(Fig. 4 J). Collectively, these data show that the miR-17∼92 
cluster promotes the in vivo function of ILC2s in the in-
duction of AA inflammation. Because a minor fraction of 
ILC2s remained Red5– in papain-challenged mice (Fig. 4 B), 
these results may underestimate the physiological effect of 
miR-17∼92 deficiency in ILC2s.
the mir-17∼92 cluster promotes ILc2 growth and 
regulates cytokine production
To understand the mechanisms by which the miR-17∼92 
cluster promotes ILC2-mediated type 2 immune responses, 
equal numbers of lung ILC2s from 17∼92+/+ or 17∼92Δ/Δ 
mice were purified and cultured in IL-33, TSLP, and IL-7. 
in vitro (TH2 in vitro). (B) Unsupervised hierarchical clustering of all DESeq2 differentially expressed miRNAs. A list of individual miRNAs in each subgroup 
is included in Table S2. (C) Heat map of log2 normalized read counts and fold changes of miRNAs significantly (adjusted P < 0.01) up- or down-regulated 
in ILC2s after culture in vitro with IL-33, TSLP, and IL-7. Values for naive CD4 T cells and T cells after 5 d of TH2 polarizing culture are also provided for 
comparison. (D) Quantitative PCR confirmation of RNA sequencing data for the indicated miRNAs. Bars represent mean ± SEM. P-values were calcu-
lated with Student’s t test.
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17∼92Δ/Δ ILC2s expressed ST2, TSL PR, and IL7R normally 
(not depicted). These stimuli induced ILC2 proliferation 
in vitro, but fewer fluorescent Red5+ cells were visible in 
17∼92Δ/Δ cultures within 4 d (Fig. 5 A). We used CyQUA NT 
assays to accurately measure ILC2s outgrowth in vitro, reveal-
ing a 60% reduction in the 17∼92Δ/Δ ILC2s present at day 4 
compared with control 17∼92+/+ cultures (Fig. 5 B). Similar 
results were observed throughout the 10-d culture period. To 
test whether the miR-17∼92 cluster affected ILC2 prolifer-
ation, we examined Ki67 expression at day 3. A significantly 
higher percentage of 17∼92+/+ ILC2s were Ki67+ compared 
with 17∼92Δ/Δ ILC2s (Fig. 5 C). Annexin V staining indicated 
no difference in the rate of apoptosis (Fig. 5, D and E). These 
data indicate that miR-17∼92 is required for normal cyto-
kine-driven ILC2 proliferation in vitro.
ILC2 cytokine production was also independently af-
fected by miR-17∼92 deficiency. 17∼92Δ/Δ ILC2s produced 
less IL-13, IL-6, and GM-CSF over 10 d of culture (Fig. 6 A). 
Because there were fewer ILC2s present in 17∼92Δ/Δ cultures 
at day 4, we also measured early cytokine secretion at day 2 
and observed a similar result (Fig. 6 B). Conversely, 17∼92tg/tg 
ILC2s produced more IL-13, IL-6, and GM-CSF than did 
their 17∼92+/+ counterparts at 10 d of culture (Fig. 6 C). IL-2, 
IL-4, and IL-10 were not detected in these culture conditions. 
For further confirmation and to determine whether cyto-
kine expression differences could be observed on a per-cell 
basis independent of cell number, we also measured cyto-
kine transcripts. Indeed, 17∼92Δ/Δ ILC2s exhibited reduced 
Il13 mRNA expression (Fig. 6 D), and 17∼92tg/tg ILC2s had 
increased Il13 expression compared with control 17∼92+/+ 
Figure 2. Severe reduction of lung ILc2s in red5 dgcr8Δ/Δ mice. (A) Contour plots depict the gating strategy for lung ILC2s in Dgcr8Δ/+ and 
Dgcr8Δ/Δ mice. Total ILC2s are identified as live CD45+CD90+lin–CD4–CD25+ cells. Among total ILC2s, tdTomato (Red5) fluorescence indicates Cre expression, 
and YFP expressed from the R26-YFP reporter indicates Cre activity. (B) Flow cytometric analysis of ST2 median fluorescence intensity (MFI) in the total ILC2s 
of Dgcr8Δ/+ and Dgcr8Δ/Δ lung. (C–F) Flow cytometric quantification of total ILC2s (C), YFP+ ILC2s (D), Red5+ YFP–ILC2s (E), and Red5– YFP–ILC2s (F) in the 
lung of Dgcr8Δ/+ and Dgcr8Δ/Δ mice. Bar graphs show ILC2 frequency as percentage of live CD45+ cells (mean ± SEM). Each data point represents an indi-
vidual mouse. Data were pooled from two independent experiments each with five to seven mice per group. P-values were calculated with Student’s t test.
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ILC2s (Fig. 6 E). However, this defect was specific to Il13, as 
17∼92Δ/Δ ILC2s expressed higher levels of Il6, Csf2 (which 
encodes GM-CSF), and Il9 (Fig. 6 D). Consistent with these 
data, 17∼92tg/tg ILC2s had decreased expression of Csf2 and 
Il9 compared with control 17∼92+/+ ILC2s (Fig. 6 E). The 
enhanced expression of Il6, Csf2, and Il9 in 17∼92Δ/Δ ILC2s 
indicates that they were fully capable of cytokine expression 
in response to IL-33, TSLP, and IL-7 in vitro, yet they display a 
specific defect in the production of type 2 cytokines. 17∼92Δ/Δ 
ILC2s also showed a per-cell reduction in IL-5 expression as 
indicated by reduced Red5-encoded tdTomato fluorescence 
intensity (Fig. 6 F). Consistent with previous findings in TH2 
cells, miR-17∼92 did not affect GATA-3 expression in ILC2s 
(Fig.  6  G). Collectively, these data demonstrate important 
roles for the miR-17∼92 cluster in promoting ILC2 prolifer-
ative capacity and regulating cytokine production.
mir-19a promotes IL-13 and IL-5 production in ILc2s
The miR-17∼92 cluster promotes type 2 cytokine ex-
pression in TH2 cells, mainly as a result of the function of 
the miR-19 family (Simpson et al., 2014). We established 
a protocol for next-generation transfection of ILC2s with 
Figure 3. mir-17∼92 cluster expression and requirement in lung ILc2s. (A) Schematic of the miR-17∼92 cluster miRNAs and their chromosomal 
positions. Colors indicate miRNAs families. (B) Heat map of log2 normalized read counts of miR-17∼92 cluster miRNAs in the indicated cell types (see Fig. 1 
legend). (C) Quantitative PCR quantification of the indicated miRNAs in 10-d-cultured 17∼92Δ/Δ and 17∼92+/+ ILC2s. Symbols indicate individual cultures 
seeded with cells from a pool of two to three mice each. Data were pooled from three independent experiments. (D and E) Flow cytometric quantification 
of total lung ILC2 and Red5+ ILC2 frequency (see Fig. 2 A legend) in 17∼92Δ/Δ (D) and 17∼92tg/tg (E) mice compared with matched 17∼92+/+ controls. Each 
ILC2 culture was started with 10,000 (B) or 3,500 (C) ILC2s sorted from individual mouse or pools of two to six mice and cultured with IL-33, TSLP, and IL-7 
for 10 d. Each data point represents the ILC2 frequency expressed as percentage of live CD45+ cells in an individual mouse. Data were pooled from two 
independent experiments. Bars represent mean ± SEM. P-values were calculated with Student’s t test.
3633JEM Vol. 214, No. 12
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small RNAs and used it to restore miR-17∼92 family 
members’ activity in 17∼92Δ/Δ ILC2s by transfecting them 
with miR-19a, miR-18a, miR-17, and miR-92a mimics 
(Fig. 7 A). All four miRNA mimics increased Il13 mRNA 
expression in 17∼92Δ/Δ ILC2s compared with control mim-
ics, although miR-19a transfection induced Il13 expression 
the most (Fig. 7 B). miR-19a transfection also significantly 
increased Il5 mRNA expression (Fig. 7 C), but it did not af-
fect Il6 (Fig. 7 D). 17∼92Δ/Δ ILC2s transfected with miR-19a 
mimic secreted significantly more IL-13 (Fig. 7 E) and IL-5 
(Fig. 7 F), but not IL-6 protein (Fig. 7 G), than cells trans-
fected with control mimic. Importantly, miR-19a rescued 
defective IL-13 and IL-5 production in the absence of other 
endogenous miR-17∼92 family miRNAs, even though it 
was delivered after 8 d of culture. 17∼92Δ/Δ ILC2s transfected 
with miR-19a also exhibited significantly higher expression 
of Ki67 mRNA than control cells transfected with control 
mimic, indicating that miR-19a affects ILC2 proliferation as 
well (Fig. 7 H). We conclude that miR-19a is an important 
member of the miR-17∼92 cluster that promotes prolifera-
tion and enhances IL-13 and IL-5 production by ILC2s in a 
cell-intrinsic manner.
mir-19a targets genes that limit IL-13 and 
IL-5 production in ILc2s
To investigate how miR-19 regulates IL-13 production 
in ILC2s, a candidate gene approach was taken. We tested 
several miR-19 target genes that had been previously con-
firmed in other cell types (Hsu et al., 2011). The mRNAs 
encoding four of these candidates (Tnfaip3, Socs1, Rora, 
and Kit) were more abundant in cultured 17∼92Δ/Δ ILC2s 
than in control 17∼92+/+ ILC2s (Fig. 8 A), consistent with 
targeting by one or more miR-17∼92 cluster miRNAs 
in ILC2s. miR-19 was sufficient to mediate repression of 
Tnfaip3, Socs1, Rora, and Kit in 17∼92Δ/Δ ILC2s, as trans-
fection with miR-19a mimic significantly reduced the ex-
pression of their corresponding mRNAs compared with 
cells transfected with control mimic (Fig. 8 B). Surprisingly, 
the well-known miR-19 target Pten was affected by neither 
miR-17∼92 deficiency nor miR-19a mimic transfection in 
ILC2s (Fig. 8, A and B).
The functional impact of miR-19 targets on ILC2 
cytokine expression was tested by transfecting 17∼92Δ/Δ 
ILC2s with siRNAs against Tnfaip3 and Socs1. Compared 
with control siRNA, Tnfaip3 and Socs1 siRNAs increased 
both IL-13 and IL-5 cytokine production and mRNA ex-
pression in ILC2s (Fig. 9, A and B). Thus, these two miR-19 
targets specifically regulated IL-13 and IL-5 production in 
ILC2s. Collectively, these data indicate that miR-19 pro-
motes type 2 cytokine production and regulates overlapping 
but nonidentical sets of functionally relevant target genes 
in ILC2 and TH2 cells.
dIScuSSIon
Extensive study of ILC2s in recent years has changed our per-
ception of TH2 cells as the central cytokine-secreting drivers 
of allergic inflammation. ILC2s have emerged as a potent early 
source of type 2 cytokines, important contributors to airway 
disease models, and a potential link between innate and adap-
tive phases of type 2 responses (Scanlon and McKenzie, 2012; 
Martinez-Gonzalez et al., 2015). Several key transcription 
factors and cytokine signals required for ILC2 development 
and maturation have been identified, yet knowledge of the 
gene expression networks that govern ILC2 biology remains 
underdeveloped (Walker and McKenzie, 2013; von Moltke 
and Locksley, 2014). In the current study, we demonstrate that 
miRNAs are absolutely critical regulators of ILC2 homeosta-
sis, and the miRNAs of the miR-17∼92 cluster in particular 
are required for normal ILC2 survival, cytokine production, 
and allergic responses. One of these, miR-19, promoted IL-13 
production and targeted inhibitors of the NF-κB and STAT 
pathways that mediate innate cytokine signals upstream of 
Il13 expression in ILC2s. These findings illustrate how the 
network logic of miRNA function allows them to regulate 
common biological outcomes through overlapping but dis-
tinct target gene repertoires in different cellular contexts, such 
as ILC2s and TH2 cells.
The expression and importance of miRNAs in T, B, 
and natural killer cells has been well established (Fehniger 
et al., 2010; Baumjohann and Ansel, 2013; Beaulieu et al., 
2013; de Yébenes et al., 2013) but miRNAs were heretofore 
largely unexplored in other lymphocytes. Global disruption 
Figure 4. mir-17∼92 cluster enhances ILc2 function in AA inflammation. (A) 4-d experimental model of papain-induced airway inflammation. 
Red5 heterozygous 17∼92Δ/Δ and 17∼92+/+ mice received 35 µg papain in 40 µl PBS or PBS alone oropharyngeally on three consecutive days, and lung 
tissue samples were harvested on day 4. (B) Flow cytometric enumeration of total ILC2s and Red5+ ILC2s in the lung. (C and D) Flow cytometric quantifi-
cation of the number of eosinophils (Siglec-F+CD11c–) and CD4+ T cells recovered in BAL (C) and digested lung tissue (D). (E) Cytometric bead array (CBA) 
measurement of IL-13 and IL-5 in BAL fluid. (F) Quantitative PCR (qPCR) quantification of Il13 and Il5 mRNA in total lung cells, normalized to Gapdh mRNA. 
(G) Representative flow cytometric analysis of intracellular cytokine staining (top). Numbers in quadrants indicate percentage of cytokine-producing live, 
Lin−CD45+CD90+CD4− ILCs. Bar graphs (bottom) show frequencies of lung ILCs expressing IL-5, IL-13, or both IL-5 and IL-13. (H) 6-d experimental model of 
papain-induced airway inflammation. (I) Inflammation score from hematoxylin and eosin staining of lung sections (see Materials and methods). Note the 
thicker and more circumferential inflammatory infiltrates cuffing a representative 17∼92+/+ versus 17∼92Δ/Δ mice bronchiole (B, top) and vessel (V, bottom). 
The thickness of the bronchiole or vessel wall without inflammation is highlighted by a dashed white line for reference. Bars, 40 µm. (J) qPCR quantification 
of IL-13–induced repair genes in epithelial brushing of papain-treated mice. Data are representative of three independent experiments each with 5–10 mice 
in each group (A–F). Bars represent mean ± SEM. P-values were calculated using one-way ANO VA with Sidak’s multiple comparison between papain-treated 
17∼92+/+ and 17∼92Δ/Δ mice (B–F) or with Student’s t test (G–J).
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of miRNA biogenesis by inactivating Dgcr8 in Il5-expressing 
cells provoked extensive loss of ILC2s, revealing a critical role 
for miRNAs in ILC2 homeostasis. In addition, we identified 
the miRNA repertoire of resting and cytokine-activated 
murine ILC2s, providing critical information and a framework 
for formulating questions about miRNA participation in the 
regulatory circuits that control ILC2 biology. Consistent with 
their similar gene expression and cytokine production profiles 
(Van Dyken et al., 2016), ILC2s and TH2 cells exhibited 
broadly shared miRNA repertoires. It is tempting to speculate 
that miRNAs expressed in both ILC2s and TH2 cells might 
regulate common pathways that determine their similar 
immune effector phenotypes. Indeed, our analysis of miR-19 
demonstrates that overlapping but nonidentical miRNA 
:target networks govern common functional behaviors 
in ILC2s and TH2 cells.
In addition, ILC2s actively reset their miRNA reper-
toire when stimulated with TSLP and IL-33, similar to the 
behavior of T cells activated by antigen stimulation (Brone-
vetsky et al., 2013). This finding suggests that the post-
transcriptional down-regulation of mature miRNAs and 
concurrent changes in primary miRNA transcription that 
rapidly establish a new pattern of miRNA expression in ac-
tivated T cells may operate similarly downstream of cytokine 
signals in ILC2s. We observed this dynamic cytokine-induced 
change in miRNA expression in ILC2s stimulated in vitro, 
but very similar profiles of miRNA expression in ILC2s 
harvested from lungs with and without IL-33 exposure in 
vivo. Either IL-33 is insufficient to drive miRNA expression 
changes in the context of the tissue microenvironment, or 
miRNA expression recovers to homeostatic levels rapidly 
after the IL-33 source is exhausted.
A few miRNAs exhibited markedly different expression 
patterns in ILC2s and TH2 cells. For example, miR-126 was 
abundant in ILC2s and strongly down-regulated upon cy-
tokine activation, but scarcely expressed in naive T cells and 
moderately up-regulated in differentiated TH2 cells in vitro 
and in vivo. Because miR-126a antagonists inhibit the re-
sponse to house dust mite allergen in a mouse model of asthma 
(Mattes et al., 2009), these findings raise the possibility that 
miR-126a may be functionally important for ILC2 sentinel 
function in the initiation of type 2 immune responses. It is also 
possible that a subset of tissue-resident TH2 cells may further 
modulate their expression of miR-126 and other miRNAs 
to more closely resemble the pattern observed in ILC2s.
The miR-17∼92 cluster has many established func-
tions in lymphocytes. It promotes the proliferation and sur-
vival of T cells and regulates the differentiation and function 
of several effector T cell subsets, including TH2 cells (Xiao et 
al., 2008; Jiang et al., 2011; Steiner et al., 2011; Baumjohann 
et al., 2013; de Kouchkovsky et al., 2013; Kang et al., 2013; 
Simpson et al., 2014; Han et al., 2015). All six miR-17∼92 
cluster miRNAs were expressed similarly in ILC2s and TH2 
cells, and ILC2s lacking the cluster also exhibited defective 
induction of allergic inflammation in vivo and in prolifer-
ation and type 2 cytokine production in response to TSLP, 
Figure 5. the mir-17∼92 cluster promotes ILc2s pro-
liferation. (A) Microscopic view of tdTomato fluorescence in 
Red5+ ILC2s. Bars, 200 µm. (B) CyQUA NT NF cell proliferation 
assay fluorescent quantification of 17∼92Δ/Δ and 17∼92+/+ 
ILC2s after culture for 4 d. (C) Quantification of Ki67+ 
17∼92Δ/Δ and 17∼92+/+ ILC2s frequencies after culture for 3 
d. (D and E) Apoptosis in 17∼92Δ/Δ and 17∼92+/+ ILC2s was 
assessed using Annexin V and DAPI staining on day 4 of cul-
ture. Bar graphs show the percentage of dead apoptotic ILC2s 
(DAPI+ Annexin+; D) and live apoptotic ILC2s (DAPI− Annexin−; 
E). NS, not significant. Data in A, B, D, and E are representative 
of at least 20, 4, and 2 independent experiments, respectively. 
Bars represent mean ± SEM. P-values were calculated with 
Student’s t test (B–E).
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IL-7, and IL-33 in vitro. IL-33 is a potent activator of lung 
ILC2s (Bartemes et al., 2012; Kamijo et al., 2013), and the 
genes encoding IL-33 and its receptor ST2 are major sus-
ceptibility loci for human asthma (Moffatt et al., 2010). 
ST2 surface expression was normal in resting and activated 
17∼92Δ/Δ ILC2s. Reduced IL7R expression was observed in 
miR-17∼92–deficient common lymphoid progenitors and 
thymocytes (Regelin et al., 2015). However, we observed no 
difference in IL7R or TSL PR expression in cultured ILC2s. 
Thus, modulation of signaling or gene expression down-
stream of these cytokine receptors must be responsible for 
the altered responses of 17∼92Δ/Δ ILC2s.
In miR-17∼92–deficient TH2 cells, miR-19a and 
miR-19b restored IL-13 production, but other miRNAs of the 
cluster did not (Simpson et al., 2014). miR-19a also restored 
IL-13 production in 17∼92Δ/Δ ILC2s. We identified two im-
portant pieces of the miR-19 target network in ILC2s: Tnfaip3 
and Socs1. Both of these targets encode inhibitors of cytokine 
signaling pathways, indicating that miR-19 supports the pro-
duction of IL-13 and IL-5 by simultaneously amplifying signals 
Figure 6. the mir-17∼92 cluster regulates cytokines production from ILc2s. (A and B) IL-13, IL-6, GM-CSF, and IL-9 measured by cytometric bead 
array (CBA) in supernatants from 10- and 2-d cultured 17∼92Δ/Δ and 17∼92+/+ ILC2s, respectively. (C) IL-13, IL-6, GM-CSF, and IL-9 measured by CBA in 
supernatants from 10-d cultures of 17∼92+/+ and 17∼92tg/tg ILC2s. (D and E) Quantitative PCR quantification of Il13, Il6, Csf3, and Il9 in 10-d cultured ILC2s, 
normalized to Gapdh. (F) Red5 tdTomato median fluorescence intensity (MFI) in 4-d-cultured ILC2s, assessed by flow cytometry as an indirect measure of Il5 
expression. (G) Flow cytometry analysis of GATA-3 expression in 17∼92Δ/Δ and 17∼92+/+ ILC2s at day 3 of culture, presented as MFI of GATA-3 expression in 
live singlet. Each culture was started with 3,500 (A–F) ILC2s, sorted from an individual mouse or pools of two to three mice, and cultured with IL-33, TSLP, 
and IL-7. Data in A and B are representative of at least 10 independent experiments. Data in D are pooled from three independent experiments. Data in F are 
representative of two independent experiments. Bars represent mean ± SEM. P-values were calculated with Student’s t test (A–G).
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downstream of IL-33 and IL-7/TSLP. Tnfaip3 encodes A20, a 
powerful negative regulator of the NF-κB pathway previously 
identified as an important target of miR-19 in macrophages 
and TH2 cells (Gantier et al., 2012; Simpson et al., 2014). SOCS1 
inhibits the JAK-STAT pathway downstream of IL-7 and other 
related cytokines, and also limits type 2 cytokine production in 
TH2 cells (Simpson et al., 2014). Our analysis in ILC2s revealed 
a limiting role for both of these miR-19 target genes, as deplet-
ing each individually with siRNAs was sufficient to markedly 
increase IL-13 and IL-5 production. These findings suggest that 
both A20 and SOCS1 are important miR-19 targets that reg-
ulate the ILC2 effector function. Genome-wide approaches 
to determine the full miR-19 target network in ILC2s would 
probably reveal additional targets involved in ILC2 biology.
The tumor suppressor Pten is another important 
miR-19 target that has been implicated in miRNA control 
of many biological processes (Baumjohann and Ansel, 2013). 
However, Pten expression was unaltered by miR-17∼92 de-
ficiency or miR-19a mimic transfection into ILC2s. Genetic 
rescue of the Pten overexpression observed in miR-17∼92–
deficient TH2 cells partially restored IL-13 production (Simp-
son et al., 2014), but apparently this mode of regulation is not 
operational in ILC2s. In contrast, two miR-19 targets that are 
not highly expressed in TH2 cells were regulated by miR-19 
in ILC2s: Kit and Rora. c-Kit is a receptor tyrosine kinase 
often used to identify mouse and human ILC2 cells. Rora is 
a direct target of multiple miR-17∼92 cluster miRNAs, and 
aberrant expression of the transcription factor that it encodes, 
RORα, disrupts the fidelity of lineage-specific gene expres-
sion in miR-17∼92–deficient follicular helper T cells (Baum-
johann et al., 2013). RORα is critical for ILC2 development, 
but little is known about its contribution to functional aspects 
of ILC2 biology (Wong et al., 2012). Polymorphisms in the 
human RORA locus are associated with asthma susceptibility 
(Moffatt et al., 2010). Future studies may uncover additional 
functionally relevant miR-17∼92 targets in ILC2s.
Figure 7. cell-intrinsic defect in IL-13 
and IL-5 production in 17∼92Δ/Δ ILc2s 
rescued by mir-19a. (A) 10-d experimen-
tal model of next-generation transfection of 
ILC2s. Each culture was started with 10,000–
12,000 17∼92Δ/Δ ILC2s sorted from the pool of 
three to six mice and cultured with IL-33, TSLP, 
and IL-7. Cells were transfected on day 8 with 
control mimic (CM) or mimics of miR-19a, 
miR-18a, miR-17, and miR-92a and harvested 
on day 10. (B–D) Quantitative PCR (qPCR) 
quantification of Gapdh-normalized Il13, Il5, 
and Il6 mRNA from 17∼92Δ/Δ ILC2s trans-
fected with CM or miR-19a, miR-18a, miR-17, 
and miR-92a mimic. (E–G) IL-13, IL-5, and IL-6 
measured by cytometric bead array (CBA) in 
supernatants from 17∼92Δ/Δ ILC2s transfected 
with miR-19a or control miRNA mimic. Data 
are pooled from five independent experiments 
and are normalized to matched control mimic 
transfection in each biological replicate. Bars 
represent mean ± SEM. (H) qPCR quantifi-
cation of Gapdh-normalized Ki-67 mRNA 
expression from 17∼92Δ/Δ ILC2s transfected 
with miR-19a or control miRNA mimic. Bars 
represent mean ± SEM. Data in B–D and H are 
pooled from two independent experiments. 
P-values were calculated with one-way ANO 
VA with Dunnett’s multiple comparison post 
hoc test (comparing each column to CM; B–D), 
paired Student’s t test on unnormalized data 
(E–G), or Student’s t test (H).
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In addition to augmenting IL-13 and IL-5 produc-
tion, miR-17∼92 surprisingly reduced ILC2 expression 
of Il9, Il6, and Csf2 (GM-CSF). These latter effects were 
not rescued by transfection with mimics corresponding to 
each miRNA family in the miR-17∼92 cluster, although 
transgenic overexpression of the entire cluster reduced Il9 
and Csf3 expression. These findings verify that 17∼92Δ/Δ 
ILC2s are capable of efficient cytokine production and 
highlight the specificity of miR-19 regulation of IL-13 and 
IL-5. In addition, they suggest that multiple miR-17∼92 
miRNAs act in concert to coordinate regulatory net-
works that control ILC2 cytokine production and expan-
sion in response to IL-33.
In conclusion, this study provides concrete evidence 
that miRNAs regulate diverse aspects of ILC2 biology. 
Using mouse genetic tools and a novel protocol for ILC2 
transfection with siRNAs and miRNA mimics, we dissected 
the mechanism by which the miR-17∼92 cluster regulates 
type 2 cytokine production. miR-19a regulates IL-13 pro-
duction through overlapping but nonidentical downstream 
target networks in ILC2s and TH2 cells, suggesting that 
miR-19a itself might be an attractive therapeutic target (Lu 
and Rothenberg, 2013). Alternatively, targeting the same sig-
naling pathways modulated by miR-19 could be an effec-
tive intervention for asthma and allergic diseases (Edwards 
et al., 2009). Our findings open new avenues for under-
standing the gene expression programs and signaling path-




Mice with loxP-flanked alleles encoding miR-17∼92 (Mirc1fl/fl, 
008458; The Jackson Laboratory) and Rosa26-Mir-17∼92-
transgenic mice Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)RSKY, 
008517; The Jackson Laboratory) were crossed to 
Il5tm1.1(cre)LKy (Red5) mice (Nussbaum et al., 2013) to de-
lete the floxed alleles specifically in IL-5–producing cells. 
Dgcr8tm1.1Blel (Dgcr8fl/fl); Gt(ROSA)26Sortm3(CAG-EYFP)Hze 
(Rosa-YFP; Rao et al., 2009) were provided by R. Blelloch 
(University of California, San Francisco) and crossed with 
Red5 mice to generate Red5 Dgcr8fl/fl ROSA-YFP mice 
(here Dgcr8Δ/Δ). Il4tm1LKy (4get) mice have been described 
previously (Mohrs et al., 2001). Male and female mice used 
were 5–9 wks of age on the C57BL/6 background (≥10 
backcross generations). All mice were housed and bred in the 
specific pathogen–free barrier facility at the University of 
California, San Francisco. The Institutional Animal Care and 
Use Committee at the University of California, San Fran-
cisco, approved all animal experiments.
Figure 8. mir-19 regulates target gene expression in ILc2s. (A) Quantitative PCR (qPCR) quantification of the indicated candidate miR-19a target 
mRNAs in 10-d-cultured 17∼92+/+ and 17∼92Δ/Δ ILC2s. (B) qPCR quantification of mRNAs in 17∼92Δ/Δ ILC2s transfected with control mimic (CM) or 
miR-19a mimic (19a). Data are normalized to Gapdh mRNA. Each culture was started with 3,500 (A) or 10,000 (B) ILCs, sorted from pools of two to six 
mice. Data are pooled from three independent experiments (A and B). Bars represent mean ± SEM. P-values were calculated with Student’s t test (A) or 
paired Student’s t test (B).
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Lung digestion
For flow cytometric analysis or sorting of ILC2s, lungs were 
perfused with PBS via the right ventricle until it blanched. 
Lung lobes were excised and processed with a gentleMACS 
automated tissue dissociator in C tubes (Miltenyi Biotec), 
running program “m_lung_01,” followed by shaking incu-
bation for 35 min at 37°C, 175 rpm, in RPMI medium 
containing 50 µg/ml Liberase TM and 25 µg/ml DNAs1 
(Roche). After incubation, a second dissociation was per-
formed with program “m_lung_02.” After tissue dissocia-
tion, cell suspensions were filtered through a 70-μm nylon 
mesh, washed, and treated with BD Pharm Lyse lysing solu-
tion (BD Biosciences) to lyse red blood cells before final 
suspension in PBS with 3% FBS.
Flow cytometry and sorting
Monoclonal, murine-specific antibodies from BioLegend in-
cluded anti-B220 (RA3-6B2), anti–Gr-1 (RB6-8C5), anti- 
F4/80 (BM8), anti-CD3 (145-2C11), anti-CD49b (DX5), 
anti-NK1.1 (PK136), anti-CD4 (RM4-5), anti-CD11c 
(N418), anti-CD4 (GK 1.5), anti-CD8a (53–6.7), and 
anti–IL-5 (TRFK5). Antibodies from eBioscience included 
anti-CD25 (PC61.5), anti-CD90.2 (53–2.1), anti-CD4 
(GK1.5), anti-CD4 (RM4.5), anti-CD11b (M1/70), and 
anti–Ly-6G (RB6-8C5). Antibodies from BD Biosciences 
included anti-CD11C (HL3), Streptavidin, anti-CD45 (30-
F11), anti–Siglec-F (E50-2440), anti-Ki67 (SolAI5), anti–
IL-13 (eBio13A), and anti-GATA3 (TWAJ). Antibodies 
from TON BO Biosciences included anti-CD11b (M1/70). 
Nonspecific antibody binding was blocked with anti-CD16/
CD32 plus 2% normal mouse/rat serum. Dead cells were ex-
cluded with Fixable Viability Dye eFluor780 (eBioscience). 
Sample data were acquired with a LSR II flow cytometer (BD 
Biosciences) and analyzed using FlowJo software. Cells were 
sorted using a FACS Aria II (Beckman Coulter).
For measurement of intracellular cytokine expres-
sion, cells were isolated ex vivo and stimulated in complete 
high-glucose DMEM supplemented with 10% heat-inacti-
vated FBS, penicillin/streptomycin/l-glutamine, 2-mercap-
toethanol with 50 ng/ml phorbol 12-myristate 13-acetate 
(Sigma-Aldrich), 500 ng/ml ionomycin (Sigma-Aldrich), and 
10 µg/ml brefeldin A (Sigma-Aldrich) for 4  h. Cells were 
stained with the viability dye eFluor780 and fixed in 4% PFA 
for 8 min at room temperature. Cytokine staining was done 
in permeabilization buffer containing 0.5% saponin (Invitro-
gen). For analysis of transcription factor expression, cultured 
cells were fixed and permeabilized according to the manu-
facturer’s instructions (Foxp3/Transcription Factor Staining 
Buffer Set; eBioscience).
In vitro cultures and transfection
Sorted ILC2s were cultured (37°C, 10% CO2) at 3,000–
10,000 cells per well in 200  µl high-glucose DMEM sup-
plemented with 10% heat-inactivated FBS, penicillin/
streptomycin/l-glutamine, 2-mercaptoethanol, recombinant 
mouse cytokines, IL-33, TSLP, and IL-7 at 10 ng/ml (R&D 
Figure 9. mir-19 targets tnfaip3 and 
Socs1 negatively regulate IL-13 and IL-5 
expression in ILc2s. (A) IL-13 and IL-5 mea-
sured by cytometric bead array (CBA) in super-
natants from 17∼92Δ/Δ ILC2s transfected with 
siRNAs targeting Tnfaip3 or Socs1 or negative 
control siRNA (siNegCtl). (B) Quantitative PCR 
quantification of Il13 and Il5 mRNA, normal-
ized to Gapdh mRNA. Each culture was started 
with 10,000 ILC2s sorted from pools of five to 
seven mice. Data are pooled from three inde-
pendent experiments. P-values were calcu-
lated with paired Student’s t test.
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Systems). At harvest, cell-free culture supernatants were col-
lected, and cells were analyzed by flow cytometry or collected 
in TRIzol LS (Thermo Fisher Scientific) for RNA extraction. 
On day 8 of culture, ILC2s were transfected with miRNA 
mimics and siRNAs (Dharmacon). miRID IAN miRNA 
mimics were used at 500 nM per transfection. siGEN OME 
SmartPools and ON-TAR GETplus Individual siRNAs were 
used at 500 nM. Cells were transfected using the Neon Trans-
fection system (Invitrogen) as previously described (Steiner et 
al., 2011). Cells and culture supernatants were harvested on 
day 10 for further analysis.
cyQuA nt nF cell proliferation assay
CyQUA NT NF Cell Proliferation Assay kit (Thermo Fisher 
Scientific) was used to measure proliferation of 4-d-cul-
tured ILC2s, which were analyzed on a FLUOstar Optima 
plate reader (BMG Labtech).
cytokine protein analysis
For ILC2 culture supernatants and BAL, IL-13, IL-5, IL-9, 
IL-6, and GM-CSF were quantified by cytometric bead 
array using a LSR II flow cytometer and FCAP Array analysis 
software (BD Biosciences).
rnA isolation and quantitative rt-Pcr
ILC2s, CD4+ T cells, and TH2 cells were sorted directly into 
TRIzol LS (Thermo Fisher Scientific). Cultured ILC2s, TH2 
cells, or gentleMACS-homogenized lung cells were also 
frozen in TRIzol LS (Thermo Fisher Scientific), and RNA 
was isolated using the miRNeasy Micro kit (Qiagen). RNA 
was reverse-transcribed with the SuperScript III kit (Invit-
rogen). Primers used for SYBR Green PCRs are as follows: 
Gapdh: 5′-GTG TTC CTA CCC CCA ATG TGT-3′, 5′-ATT 
GTC ATA CCA GGA AAT GAG CTT-3′; Il9: 5′-ATG TTG 
GTG ACA TAC ATC CTT GC-3′, 5′-TGA CGG TGG ATC 
ATC CTT CAG-3′; Il5: 5′-CTC TGT TGA CAA GCA ATG 
AGA CG-3′, 5′-TCT TCA GTA TGT CTA GCC CCTG-3′; 
Il13: 5′-CCT GGC TCT TGC TTG CCTT-3′, 5′-GGT CTT 
GTG TGA TGT TGC TCA-3′; Csf2: 5′-GTC TCT AAC 
GAG TTC TCC TTC A-3′, 5′-CCT TGA GTT TGG TGA 
AAT TGCC-3′; Il6: 5′-AGC CAG AGT CCT TCA GAGA-
3′, 5′-TCC TTA GCC ACT CCT TCT GT-3′; Rora: 5′-CTT 
CTC GGT GGT TCT TCT GT-3′, 5′-TTC TGC ATT CGT 
ACT GAT GTCA-3′; Socs-1: 5′-ATT CCA CTC CTA CCT 
CTC CAT-3′, 5′-CAG AAA AAT GAA GCC AGA GACC-3′; 
Tnfaip3: 5′-AGA ACC AGA GAT TCC ATG AAGC-3′, 5′-
CTG TGT AGT TCG AGG CAT GT-3′; Kit: 5′-CCA TAG 
GAC CAG ACA TCA CTT-3′, 5′-CTA GCC AGA GAC ATC 
AGG AATG-3′; Pten: 5′ TAA TAT ACA TAG CGC CTC 
TGA CTG-3′, 5′-CGG ACT GGT GTA ATG ATT TGTG-3′; 
Muc5ac: 5′-CAG GAC TCT CTG AAA TCG TAC CA-3′, 5′-
AAG GCT CGT ACC ACA GGGA-3′; Clca3: 5′-CTG TCT 
TCC TCT TGA TCC TCCA-3′, 5′-CGT GGT CTA TGG 
CGA TGA CG-3′; and Gob5: 5′-CAT CGC CAT AGA CCA 
CGA CG-3′, 5′-TTC CAG CTC TCG GGA ATC AAA-3′.
In vivo allergic inflammation model
Mice were anesthetized using isoflurane inhalation and chal-
lenged with 35 µg papain (Calbiochem) in 40  µl PBS ad-
ministered to the lungs by oropharyngeal aspiration daily for 
three consecutive days. Samples were harvested on day 4. BAL 
was performed by three consecutive washes of 1  ml com-
plete medium. The number of cells in BAL and lung samples 
was quantified by FACS analysis with AccuCount Particles 
(Spherotech). For lung pathology, mice were challenged with 
35 µg papain in 40 µl PBS on days 1, 3, and 5, and samples 
were harvested on day 6. A blinded pathologist scored in-
flammation in lungs on day 6 using routine hematoxylin and 
eosin–stained paraffin sections. Both the right and left lungs 
were examined. Perivascular, peribronchiolar, and interstitial/
alveolar inflammation was scored for percentage involvement 
(0% = 0, 1–25% = 1, 26–50% = 2, 51–75% = 3, and 76–
100% = 4). Perivascular and peribronchiolar inflammation 
was also scored for the mean thickness of the inflammatory 
cuff (0 cells = 0, 1–3 cells = 1, and ≥4 cells = 2). The values 
were summed for each sample to determine the inflamma-
tion score. One mouse was excluded because of histological 
evidence of acute bronchopneumonia, and two mice were 
excluded for a paucity of bronchioles available for evaluation.
Small rnA sequencing
5–50 ng total RNA from sorted and/or cultured ILC2 and T 
cell samples were used to build small RNA libraries as previously 
described (Williams et al., 2013). Libraries were sequenced 
on a HiSeq2500 (Illumina). Data were demultiplexed and 
adapters trimmed using the FastX Toolkit (http ://hannonlab 
.cshl .edu /fastx _toolkit /index .html). Sequence alignment and 
small RNA read counts were obtained using the exceRpt 
small RNA-seq Pipeline (v3; https ://www .genboree .org /
epigenomeatlas /genboreeWorkbench .rhtml). Comparative 
expression analysis was performed with DESeq2 (Love et al., 
2014). Raw RNA sequencing data were deposited in the GEO 
database (GSE96934). Three or four biological replicates were 
collected for each cell type and condition. ILC2 cells were 
sorted from the lungs of control mice (ILC2) or the lungs 
of mice killed 1 d after treatment for three consecutive days 
with 500 ng IL-33 (R&D Systems) instilled by oropharyngeal 
aspiration (ILC2 IL33). Sorted ILC2s from control mice were 
also cultured in vitro for 10 d with 10 ng/ml IL-33, TSLP, 
and IL-7 from R&D Systems (ILC2 in vitro). Naive CD4+ 
T cells were sorted from pooled spleen and lymph nodes of 
control mice (CD4). TH2 cells were generated in vitro under 
polarizing conditions including 500 U/ml IL-4 supernatant 
and anti-IFNγ (TH2 in vitro) as described (Pua et al., 2016). 
An in vivo population of TH2 cells was generated by the 
induction of AA responses to OVA as previously described 
(Pua et al., 2016), with slight modification: 4get mice were 
sensitized with three weekly i.p. injections of OVA-alum and 
challenged with OVA in the lung for three consecutive days by 
oropharyngeal aspiration, and CD4+GFP+ TH2 cells were then 
sorted from BAL fluid 1 d after the final challenge (TH2 AA).
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For ILC2, ILC2 IL33, CD4, and TH2 AA, 8,000-
1,000,000 cells were sorted on either FAC SAria II or 
FAC SAria IIIu (BD Biosciences) directly into TRIzol 
LS (Thermo Fisher Scientific). For sorting, the fol-
lowing gating strategies were used: ILC2, ILC2 IL33, 
and ILC2 in vitro: CD45+Thy1+lin–CD4–CD25+ST2+; 
CD4: CD4+CD62LhiCD44loCD25–CD69–; and TH2 AA: 
CD45+CD11c−CD11b−CD4+CD3+4get+. For ILC2 in 
vitro, 10,000 sorted cells were seeded into wells, and the en-
tire cell population was lysed in TRIzol LS after 10 d of 
culture. For TH2 in vitro, 3,000,000 cells were collected from 
TH2-polarizing cultures at day 5 and lysed with TRIzol LS. 
Total RNA was isolated using a miRNeasy Micro kit (Qia-
gen), and RNA was quantified using an RNA Pico kit on 
the Bioanalyzer (Agilent).
Statistical analysis
Excel (Microsoft) and Prism (Graph Pad Software) were 
used for data analysis. Unless otherwise specified, p-values 
were calculated using unpaired Student’s t tests. For com-
parisons of multiple groups, ANO VA was used with appro-
priate post hoc testing.
online supplemental material
Table S1 summarizes mapped reads for small RNA sequenc-
ing of ILC2s and T cells. Table S2 details differential expres-
sion analyses for all pairwise comparisons of ILC2, ILC2 IL33, 
ILC2 in vitro, CD4, TH2 AA, and TH2 small RNA sequencing 
miRNA expression data. Table S3 lists miRNAs in groups 
of hierarchically clustered rows from differential expression 
analysis of small RNA sequencing data in ILC2 and T cell 
samples. Table S4 provides DESeq2 normalized miRNA ex-
pression for ILC2 and T cell samples. Tables S1–S4 are pro-
vided as zipped Excel files.
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